Oxford Biodynamics Shares Soar over 115% on JAVELIN Bladder 100 Trial News

JCI First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors

Contemporary cancer treatment strategies are shifting toward targeted therapies to improve efficacy and minimize toxicity. Here, we report the design and preclinical evaluation of MBRC-101, a first-in-class antibody-drug conjugate (ADC) targeting EphA5, a receptor tyrosine kinase with an established role in embryonic development but not extensively studied in cancer. We show that EphA5 is expressed in multiple solid tumors, including cancers of …

Targeted Therapies Improve Outcomes in Muscle-Invasive Bladder Cancer

The post Targeted Therapies Improve Outcomes in Muscle-Invasive Bladder Cancer appeared first on European Medical Journal.

Oxford Biodynamics Shares Soar over 115% on JAVELIN Bladder 100 Trial News

Pfizer publishes on successful use of EpiSwitch biomarkers evaluating tumour status and treatment outcomes from the JAVELIN Bladder 100 Trial ·      Results strongly support the use of EpiSwitch blood-based biomarkers asRead More...

AIM movers: Pfizer confirms efficacy of Oxford BioDynamics EpiSwitch and Sosandar write down reduces profit

Oxford BioDynamics (LON: OBD) says Pfizer has published information on its use of EpiSwitch biomarkers as a liquid biopsy in evaluating tumours and treatment outcomes for the JAVELIN bladder 100 trial. The EpiSwitch test can determine whether a tumour has high or low immune activity. This confirmation of efficacy will help to grow EpiSwitch sales. […] The post AIM movers: Pfizer confirms efficacy of Oxford BioDynamics EpiSwitch and Sosandar writ…

AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer - Express Pharma

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO), to import and distribute Durvalumab solution for infusion for an additional indication in India. The newly approved indication allows the use of Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Durvalumab as adjuvant treatment following radical cystectomy, for the treatment of adu…